Table 1 Patient demographics and characteristics
Characteristics | Present study population (n = 99) | Relapse free at 3 years (n = 356) | Differences between the groups (P values) |
|---|---|---|---|
Age at diagnosis (years) | |||
Mean (median) | 58 (56) | 57 (56) | |
Range | 34–78 | 28–85 | 0.380 |
Menopause status, n (%) | |||
Pre (< 55 years) | 40 (40%) | 151 (42%) | |
Post (≥ 55 years) | 59 (60%) | 205 (58%) | 0.710 |
Histology, n (%) | |||
IDC | 74 (75%) | 251 (76%) | 0.109 |
ILC | 24 (24%) | 69 (19%) | |
Other infiltrating cancer | 1 (1%) | 16 (5%) | |
Tumor size, n (%) | |||
pT1 | 50 (51%) | 253 (71%) | < 0.001* |
pT2 | 49 (49%) | 87 (25%) | |
pT3 | – | 12 (3%) | |
pT4 | – | 0 (0%) | |
pTx | – | 3 (1%) | |
Tumor grade, n (%) | |||
G1 | 18 (18%) | 110 (31%) | 0.009 |
G2 | 67 (68%) | 184 (52%) | |
G3 | 12 (12%) | 56 (15%) | |
Not reported | 2 (2%) | 6 (2%) | |
Node status, n (%) | |||
Positive | 57 (58%) | 93 (71%) | < 0.001 |
Negative | 41 (41%) | 257 (27%) | |
Not reported | 1 (1%) | 6 (2%) | |
HER2/neu status, n (%) | |||
HER2+ | 7 (7%) | 36 (10%) | 0.193 |
HER2– | 89 (90%) | 298 (84%) | |
Unknown | 3 (3%) | 22 (6%) |